Skip to main content
. 2019 Jun 14;4(2):88–101. doi: 10.1089/can.2018.0025

FIG. 5.

FIG. 5.

PDR in untreated and CB2 agonist (JWH-133 and HU-308)- and CB2 antagonist (AM-630 and SR-144528)-treated wild-type and cnr2upr1/upr1 6-dpf larvae. (A) Averaged distance traveled per minute by JWH-133-treated (top panel, 50 μM) wild type (dark green line and squares) and cnr2upr1/upr1 (light green line and squares); and HU-308-treated (bottom, 10 μM) wild type (brown line and squares) and cnr2upr1/upr1 (khaki line and squares). (B) Averaged distance traveled per minute by AM-630-treated (top panel, 3.5 μM) wild type (dark blue line and squares) and cnr2upr1/upr1 (light blue line and squares); and SR-144528 (bottom, 10 μM) wild type (purple line and squares) and cnr2upr1/upr1 (pink line and squares). Control-untreated wild-type (black line) and cnr2upr1/upr1 larvae (red line) are represented in filigree in each graph. Error bars represent the SEM. Statistical significance compares (1) treated wild type versus treated mutant=black* in all graphs, (2) untreated mutant versus treated mutant=light green* in (A)-top panel, khaki* in (A)-bottom panel, light blue* in (B)-top panel, and pink* in (B)-bottom panel, (3) untreated wild type versus treated wild type=green* in (A)-top panel, brown* in (A)-bottom panel, dark blue* in (B)-top panel, and purple* in (B)-bottom panel. *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001, and for clarity ns is omitted.